Aug 15, 2024 | Food and Drug Administration (FDA), MDMA (ecstasy), Psychedelic drugs
The potential for psychedelic drugs to serve legitimate medical purposes has become a growing topic of discussion. On August 9, the Food and Drug Administration rejected midomafetamine (MDMA), better known as ecstasy, as a treatment for post-traumatic stress disorder....
Aug 5, 2024 | Biosimilar, Cost Savings, Food and Drug Administration (FDA), Humalog, Opinions, Savings
From a STAT opinion piece by Juliana M. Reed, executive director of the Biosimilars Forum: “Biologic medicines are some of the most important drugs in the world. They are also among the most expensive. Biosimilars are FDA-approved treatments that are similar to...
Jul 23, 2024 | Federal Trade Commission (FTC), Formularies, News, Pharmacy Benefits Manager (PBM)
In an interim report released on July 9, the Federal Trade Commission charges major pharmacy benefit managers of engaging in business practices designed to benefit their own bottom lines at the expense of clients. The FTC report, subtitled “The Powerful...
Jul 5, 2024 | Biosimilar, Cost Savings, Drug costs, Humira, Idacio, MedBen Rx, News, Rx Costs, Savings
The Food and Drug Administration is considering a change to its biosimilar policy that would greatly speed up their approval process – which, if enacted, would be a big win for MedBen Rx clients who are already reducing their prescription drug spend through...
Jun 10, 2024 | Affordable Care Act, Caroline Fraker, Wegovy, Weight loss, Weight loss drugs, Zepbound
While most health plans do not currently cover obesity medications like Wegovy and Zepbound – and MedBen Rx recommends clients continue not to do so – constant media coverage means the calls to do so will only grow. Therefore, employers are increasingly considering...
